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Abstract 
The Institute for Clinical and Economic Review (ICER) announced at the end of March 2018 that it proposed to share executable draft 
economic models with relevant drug manufacturers during ICER evidence reviews. Taken at face value, ICER is offering manufacturers 
and other interested parties the possibility of a greater involvement in the assessment of modeled claims for product pricing. The 
purpose of this commentary is to point to the obvious limitations to this policy and to raise questions as to the extent to which ICER is 
willing to commit to transparency in the creation of modeled claims. While a commitment to greater transparency is to be welcomed, 
the fact remains that the ICER methodology does not meet the standards of normal science. ICER modeled claims not only lack 
credibility but are impossible to evaluate or replicate in treating environments. In proposing greater transparency ICER runs the risk of 
undermining its own credibility. If manufacturers have the opportunity to generate alternative models which create alternative claims, 
then ICER runs the risk of its pole position in health technology assessment being questioned. Rather than focused on non-evaluable 
lifetime modeled claims, there is the opportunity for ICER to reject its current business model, accepting instead a modelling paradigm 
that is consistent with the standards of normal science. 
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Introduction 
A recent commentary by the present author in INNOVATIONS 
in Pharmacy addressed the issue of the apparent unwillingness 
of the Institute for Clinical and Economic Review (ICER) to 
engage in a comprehensive and meaningful assessment of the 
structure and assumptions of the various cost-effectiveness 
models that support their reviews and pricing 
recommendations. While the commentary asked readers to 
reject the ICER methodology, which other previous 
commentaries have criticized, the absence of standards for a 
formal review procedure of ICER models was seen as a barrier 
to understanding the limitations of the ICER methodology. 
Whether in response to this critique or not, ICER on 30 March 
2018 issued a press release announcing a new Program to 
make available draft executable economic models during drug 
assessment review process 1. Although details of how this 
program is to be implemented have yet to be published, the 
purpose of this commentary is to raise a number of concerns 
as to whether this is in fact an invitation to greater 
transparency or a defense of the status quo. 
 
As detailed in previous commentaries, if the standards of 
normal science are applied to the ICER modeled claims 
methodology, then ICER fails those standards2. The modeled 
claims made for competing products lack credibility because  
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they are neither evaluable nor replicable. They should be seen 
as pseudoscience 3 4. Accepting ICER modeled claim means 
rejecting standards in normal science that have been in place 
for the last 350 years 5. This point has been made in previous 
commentaries on ICER, including four evidence reviews 
together with a more recent comprehensive review of the ICER 
approach 6 7 8 9. The position taken was that rather than 
focusing on developing imaginary lifetime-cost-per-quality 
adjusted life year (QALY) models, ICER would be more usefully 
employed in focusing on credible short-term models whose 
claims could be evaluated and replicated in real world treating 
environments. This critique of the proposed ICER program for 
transparency should be seen against this background. 
  
ICER is not alone in putting to one side the standards of normal 
science in health technology assessment. The latest Canadian 
guidelines for technology assessment are quite clear: 
Economic evaluations are designed to inform decisions. As such 
they are distinct from conventional research activities, which 
are designed to test hypotheses 10. This ‘unconventional’ role 
of economic evaluations as research activities opens the door 
to what has been described in current American political 
discourse as ‘alternative facts’, where patently absurd claims 
drive policy decisions. Competing lifetime models generate 
alternative illusions; they are divorced from reality and have 
no chance of ever being falsified. Unfortunately, all too many 
people are prepared to accept this information role with no 
thought, or awareness, of these standards. The result is that 
decision makers will be faced with competing modeled claims, 
none of which can be justified in scientific terms. 
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Constrained Transparency 
In single payer health systems such as the UK, Australia, 
Canada and New Zealand, agencies can mandate both the 
standards for modeled formulary submissions as well as the 
modeling review process 11 12  13  14. In these countries the 
construction of imaginary worlds are a critical input to pricing 
and formulary decisions. In the UK, for example, the National 
Institute for Health and Care Excellence (NICE) mandates a 
lifetime cost-utility reference case model for formulary 
submissions with willingness to pay thresholds. A submission 
by a manufacturer for formulary listing is passed to an external 
review group and then finally assessed by NICE and a 
determination made.  Typically, the model will be provided in 
electronic form. The process is transparent with the 
appropriate documentation, redacted for commercial 
confidentiality, posted to the NICE web site. The review 
group’s remit is relatively wide. It can accept the 
manufacturer’s model, modify it or propose an alternative 
model framework. NICE in turn, on receipt of the model can 
consider possible corrections as part of their final review.  
 
A similar process holds in Australia with the Pharmaceutical 
Benefits Advisory Committee setting standards for formulary 
submissions to support both the clinical and cost-utility case 
for the product. An electronic version of the model is also 
requested. The model and supporting documentation are sent 
for external reviews by a contracted academic health 
technology assessment group. The PBAC then factors the 
review assessment into the decision process. The process is 
less transparent than that followed by NICE but still relies on 
the construction of an imaginary world. 
 
ICER, as an independent group, has no ability to ask a 
manufacturer to submit a modeled case for a product. Indeed, 
typically no request is made for a manufacturer to voluntarily 
submit a model for review. Rather than potentially submitting 
a model submission, ICER has contracted with academic 
collaborators to develop a draft model. The draft model is 
presented for review where manufacturers can provide 
comments. Whether the comments are accepted is a decision 
for ICER but, again typically, the model remains essentially 
unchanged.  At the same time there is only a limited time for 
manufacturer’s to comment and for the model builder’s to 
respond. To date, ICER has refused access to an electronic 
version of the model itself on the grounds that (i) the model 
builders have to retain intellectual property rights until 
possible publication and (ii) that few people are equipped 
intellectually to offer a critique of the model without the 
support of the model builders. Understandably, 
manufacturer’s feel they are being shortchanged.  
 
The proposed new ICER program still insists on the intellectual 
right of the model builders (academic collaborators) while 
offering, subject to a payment to the model builders by the 
manufacturer, access to executable files. Although not entirely 
clear, it appears to be the intention to provide manufacturers 
with some version of the draft electronic model. However: To 
protect the intellectual property of the researchers and their 
institutions, models will be shared under confidentiality or 
licensing agreements. Under these agreements, manufacturers 
will be unable to alter the model for their own purposes. In 
addition their access will be for a limited timeframe and will be 
confined to the team of individuals responsible for the review’. 
Presumably access will be limited with the manufacturer 
unable to evaluate alternative model structures. Access will be 
for a limited timeframe – although this is undefined. It is not 
clear how long the model builder’s will have to engage with 
manufacturers, agree their (additional) remuneration and 
provide access to the model so that they can become familiar 
with ‘a model’s structure, estimates, key assumptions and 
calculations. The assumption must be, hopefully, that access 
to the model and supporting data (e.g., systematic reviews) 
will be on-line and that sufficient time is given for review and 
comment. Given the complexity of such models this could 
involve an extend time period and the possible engagement of 
consultants by the manufacturer to review the model and 
provide a comprehensive critique. Also, given time and 
resource constraints it may even be possible for the 
manufacturer to create ‘alternative fact’ modeled scenarios. 
Even so, this does not mean that we should lose sight of the 
imaginary nature of these potentially competing constructs.   
 
Unfortunately, it seems unlikely, from past experience with 
ICER and their ‘need’ to generate recommendations for 
products in concert with the product receiving marketing 
approval, for adequate time to be given for review. A 
reasonable estimate would be for the manufacturer to have 3 
months to review, comment and even generate competing 
‘alternative facts’.  It might reasonably be asked that if the 
reviewer is ‘unable to alter the model’ (whatever that really 
means) what is the object of the exercise? To limit the review 
to peripheral or marginal comments regarding assumptions? 
Can the reviewer run alternative simulations within the model 
framework? Will the model building group have a watching 
brief to veto untoward attempts to run simulation or test 
alternative structural assumptions such as the Markov process 
framework for disease staging and progression? Can the 
reviewer seek specialized consulting services to support its 
assessment? Last but not least, who will draft the 
confidentiality or licensing agreement (again, whatever that 
means) to facilitate access? A further unresolved question is 
whether the academic collaborators will have the time and 
resources to engage with manufacturers in a reasonable time 
frame. If evidence from NICE as to the resources required to 
review models is any guide, then the collaborating groups are 
likely to be well understaffed. Presumably, if they cannot meet 
the demands placed upon them they can decline requests to 
contract for any engagement. 
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As stated, this policy is unlikely to satisfy stakeholders in the 
ICER assessment process. It limits the ability of manufacturers 
and other parties to undertake a meaningful assessment of the 
model. Rather than, in the case of the NICE process where an 
external assessment group has the remit and is given the time 
and resources to modify or develop a competing model, ICER 
seems intent on waiting until the last minute for any review, 
constraining the options for review and, if past experience is a 
guide, limiting the time that manufacturers and others have 
for comment.  
 
Engagement in Model Building 
If ICER is to engage in a meaningful process of review to ensure 
transparency in model development, then stakeholders need 
to be given access to the modeling teams at an early stage in 
the development of the model. The model builders should 
develop a position paper for the model detailing its proposed 
structure, treatment pathways and key assumptions. 
Systematic reviews should be documented and the 
relationship of the proposed model to others that have 
developed in the disease or treatment area detailed at an early 
stage.  
 
The model builders should also be asked whether or not they 
propose to develop, within the model framework, credible 
claims that can be evaluated within a relatively short time-
frame as feedback to formulary committees. There should be 
an explicit statement that the model is for information only 
and it is not possible in the proposed framework to develop 
evaluable claims and test hypotheses. On the other hand, if the 
model builders propose to develop credible and evaluable 
claims, then they need to propose how those claims are to be 
evaluated.  
 
Attempts to argue for an early engagement with the model 
builders will, no doubt, be resisted by ICER. Unfortunately, this 
would undercut their case for transparency. Understandably, 
stakeholders would feel that any engagement with the 
modeling process has been deliberately minimized. They 
would have no say in the initial decisions on the scope and 
content of the model. All they will be asked is if there are minor 
adjustments that might be considered, and probably rejected, 
in a brief review process. Their hands are, to use a well-worn 
cliché, tied. After all, why pay the model builders for access to 
the model when they are unable to consider changes which 
may reflect better the clinical and supporting economic 
evidence.  
 
More Alternative Facts 
While it is not the intention here to encourage alternative 
models generating alternative facts (after all, the technology 
assessment literature is replete with thousands of non-
evaluable modeled claims 15), the pole position that NICE has 
taken upon itself to occupy should be challenged. One way to 
achieve this is to give manufacturers sufficient advance 
warning so they are in a position to consider the option of 
developing alternative modeling frameworks which can 
challenge the ICER version of alternative facts. If 
manufacturers have already submitted models to agencies 
such as the NICE and the PBAC they will be in a position to meet 
ICER on a level playing field (another well-worn cliché). These 
imaginary worlds would need to be customized for the US 
market through in-house modification (to include simulating 
ICER willingness-to-pay thresholds) with their model 
accommodating the various US market segments (commercial, 
Medicare, Medicaid, VA). This puts a premium on a meaningful 
review period.  
 
There is also the question of how robust the evidence base is 
to support modeling. There is now substantial evidence to 
point to the lack of reproducibility in clinical claims 16 17. If, for 
example, key assumptions in a model are built upon a handful 
of clinical claims where there is no evidence for replication, 
then the manufacturer may be justified in claiming that 
assumptions based on those of a model have little validity. 
Similar concerns can be raised over the often second-hand and 
interpolated estimates of utility. It is no argument to say that 
we can overcome limited or weak data or its complete absence 
by a judicious choice of scenario simulations driven by 
‘reasonable yet unsupported assumptions’. 
 
Of particular interest is the modeling of adherence and 
persistence with therapy. Previous commentaries on ICER 
models have pointed out that it seems pointless to assume a 
high level of compliance (indeed, over the lifetime of the 
modeled target population) when numerous studies have 
detailed the lack of persistence with therapies with up to 50% 
of patients non-compliant within two years of an index 
prescription. If this is expected to be the case, (and who knows 
for a product being modeled which has yet to enter the 
market?) then basing cost-per-QALY claims and pricing 
recommendations on highly dubious compliance assumptions 
seems a waste of time. To this, it might be added, is the typical 
ICER modeled assumption that prices for the products and 
other direct medical costs do not change over the timeframe 
of the model. 
 
If failure to consider long-term adherence and persistence is a 
critical weakness in the ICER modeling approach then it might 
be reasonable to ask whether manufacturers, once they have 
limited access to the model, can explore different compliance 
scenarios together with future pricing scenarios. Will ICER 
allow the results of these scenarios to be presented to the ICER 
comparative effectiveness public advisory councils? Will these 
councils be allowed to have access to modeling critiques and 
alternative scenarios presented within the ‘unalterable’ 
model? 
 
Commentary FORMULARY EVALUATIONS 
 
http://z.umn.edu/INNOVATIONS                       2018, Vol. 9, No. 2, Article 1                     INNOVATIONS in pharmacy 
                                                                             DOI: https://doi.org/10.24926/iip.v9i2.1300  
4 
 
Access to Prior Modeling 
There seems to be no reason why this announced access policy 
could not be extended to re--assessments by interested 
parties of prior models that have been developed by ICER. 
Presumably, after an elapsed timeframe of 18 or 24 months 
the various academic groups who apparently hold intellectual 
rights to the models could be asked whether or not they intend 
to publish. If there is no intention to publish and ICER is 
assured that there are outside groups capable of reviewing the 
model, then the model could be reviewed.  
 
Manufacturers, for example, might have an interest in a review 
of the model if there is a concern that the initial releases of the 
model and ICER recommendations for pricing have 
commercially disadvantaged the company. A review by an 
independent assessor might point out, apart from the obvious 
point that the claims from the model are non-evaluable, that 
there are alternative modeled facts that could be developed, 
again with non-evaluable claims, but which came to quite 
different conclusions on pricing after applying the ICER 
willingness-to-pay thresholds. Part of this assessment could 
involve a review of ICER modeled assumptions. After 18 to 24 
months from product launch and formulary listing, there 
would be evidence, for the various US market segments, on 
patterns of adherence and discontinuation, the rate of market 
uptake, quality of life claims and response to therapy. These 
could be a check on the assumptions in the model with the 
model recalibrated for clinical, cost-utility claims and 
simulated pricing points. 
 
Taking ICER Seriously 
The question which remains open is whether or not 
manufacturers and their prospective clients should take the 
announced ICER program seriously. It may well be that a 
manufacturer is prepared to put ICER to one side and make the 
case, quite appropriately, that pricing and formulary decisions 
should be evidence based. Rather than basing decisions on one 
set of alternative facts among a potential multiverse of 
competing alternative facts, the ICER approach should be 
rejected in favor of a program of establishing short-term 
modeled claims with protocols developed to demonstrate how 
those claims can be evaluated. This is, as has been detailed in 
previous commentaries, the position taken in the proposed 
Minnesota guidelines for formulary submissions 18.  If, 
however, the manufacturer wishes to engage with ICER, then 
the question of transparency should be addressed and the 
case made for the option of competing economic evaluations.  
 
 
 
Conclusions 
A reasonable question is whether or not ICER is doing its best 
to limit any reviews that may undermine the ‘validity’ of the 
collaborator model. Manufacturers cannot alter the model for 
their own purposes. This presumably means that they will not 
have the ability to do a detailed reassessment and explore 
modified or competing model structures. Indeed, it is far from 
clear as to whether or not the manufacturer will have access 
to the full model for review and recalibration purposes or 
whether they will only have access to stripped down elements 
of the model and face embargoes on what elements can be 
recalibrated.  If there is a meaningful commitment to 
transparency then it must involve manufacturers at an early 
stage and with the option and opportunity of putting forward 
what they may consider alternative modeled constructs. 
 
ICER has put itself in a difficult situation and one which has 
significant risks attached. ICER appears to be attempting to 
draw a fine line between offering limited transparency in the 
hope that the model framework will not be challenged and 
offering greater transparency which gives manufacturers the 
opportunity to develop competing models that generate 
alternative facts. If alternative facts emerge from competing 
models then decision makers are in a quandary as to which to 
believe. In the absence of the ability to discriminate between 
competing empirical claims, the fallback is to a (possibly 
unseemly) argument over which model has the most realistic 
assumptions supporting its imaginary future world (or worlds 
in competing models).  
 
Given that the ICER business case rests in large part on the 
construction of imaginary modeled worlds, designed to 
‘inform’ decision makers rather than a commitment to 
developing models that generate evaluable claims, the 
presence of competing alternative facts would raise doubts as 
to ICER’s role in pricing and formulary decision making. 
Opening the door to increased transparency and the possibility 
of competing imaginary worlds may lead not only to questions 
over the value of non-evaluable competing clams and pricing 
recommendations, but to a demand for modeled claims that 
are evaluable and replicable in treating environments. In short, 
an acceptance of the standards of normal science. 
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